<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487837</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr. 2011-0440</org_study_id>
    <nct_id>NCT01487837</nct_id>
  </id_info>
  <brief_title>Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.</brief_title>
  <official_title>A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Children's Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different thromboelastometry (ROTEM) trigger
      levels for administration of human fibrinogen concentrate (Haemocomplettan P) in the
      treatment of perioperative dilutional coagulopathy during major pediatric surgery. The study
      hypothesis is that administration of fibrinogen concentrate triggered by a ROTEM FibTEM MCF &lt;
      13 mm might reduce the total amount of transfused red cell concentrate during 24 hours after
      start of surgery as compared to a trigger level of ROTEM FibTEM MCF &lt; 8 mm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of transfused red cell concentrate</measure>
    <time_frame>24 hours after start of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>coagulation measurements</measure>
    <time_frame>24 hours after start of surgery</time_frame>
    <description>influence on viscoelastic coagulation measurements (ROTEM), plasmatic coagulation testing, FXIII levels, and endogenous thrombin potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay on PICU</measure>
    <time_frame>14 days after surgery or discharge of hospital, whatever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional transfusion/blood products requirements</measure>
    <time_frame>24 hours after start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of re-bleeding, surgical revision</measure>
    <time_frame>14 days after surgery or discharge of hospital, whatever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of (severe) adverse events</measure>
    <time_frame>14 days after surgery or discharge of hospital, whatever occurs earlier</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Blood Coagulation Disorders</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Fibrinogen if FibTEM &lt; 8 mm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF &lt; 8 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrinogen if FibTEM &lt; 13 mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF &lt; 13 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human fibrinogen concentrate</intervention_name>
    <description>Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition</description>
    <arm_group_label>Fibrinogen if FibTEM &lt; 8 mm</arm_group_label>
    <arm_group_label>Fibrinogen if FibTEM &lt; 13 mm</arm_group_label>
    <other_name>Haemocomplettan P, CSL Behring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age 6 months to 17 years

          -  Scheduled for elective scoliosis surgery or major craniofacial surgery

          -  Written informed consent has been obtained

          -  Intraoperative hypofibrinogenemia according to definition of treatment groups

        Exclusion Criteria:

          -  Preexisting congenital or acquired coagulation disorder

          -  Medical history of estimated increased bleeding tendency

          -  Ongoing coagulation therapy

          -  Clinical signs or diagnosis of acute thromboembolism

          -  Intolerance of study drug

          -  Participation at another clinical trial

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zurich University Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zurich University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrinogen</keyword>
  <keyword>Blood coagulation disorders</keyword>
  <keyword>Postoperative bleeding</keyword>
  <keyword>Transfusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

